伴有其他基因异常的1q21扩增而非孤立性1q21获得是接受沙利度胺方案治疗的新诊断多发性骨髓瘤患者的不良预后因素。 - Suppr

1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.

作者信息

Grzasko Norbert, Hus Marek, Chocholska Sylwia, Pluta Andrzej, Hajek Roman, Dmoszynska Anna

出版信息

Leuk Lymphoma. 2012 Dec;53(12):2500-3. doi: 10.3109/10428194.2012.684349. Epub 2012 May 22.

DOI:10.3109/10428194.2012.684349

PMID:22497640

Abstract

摘要

相似文献

1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.

Leuk Lymphoma. 2012 Dec;53(12):2500-3. doi: 10.3109/10428194.2012.684349. Epub 2012 May 22.

Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.

Hematol Oncol. 2013 Mar;31(1):41-8. doi: 10.1002/hon.2018. Epub 2012 Jun 6.

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.

Cancer. 2011 May 15;117(10):2136-44. doi: 10.1002/cncr.25775. Epub 2010 Dec 4.

Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma.

Leuk Lymphoma. 2011 Feb;52(2):260-4. doi: 10.3109/10428194.2010.538775. Epub 2010 Dec 6.

[Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Oct;27(5):567-70. doi: 10.3760/cma.j.issn.1003-9406.2010.05.020.

[Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].

Rev Med Interne. 2007 Oct;28(10):677-81. doi: 10.1016/j.revmed.2007.04.013. Epub 2007 May 25.

Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.

Front Med. 2020 Jun;14(3):327-334. doi: 10.1007/s11684-019-0712-x. Epub 2019 Nov 29.

Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.

Biol Blood Marrow Transplant. 2010 Apr;16(4):548-54. doi: 10.1016/j.bbmt.2009.11.025. Epub 2010 Jan 18.

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.

Leuk Lymphoma. 2017 Sep;58(9):1-15. doi: 10.1080/10428194.2016.1272684. Epub 2017 Jan 16.

The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.

Clin Cancer Res. 2015 May 1;21(9):2148-56. doi: 10.1158/1078-0432.CCR-14-2576. Epub 2015 Feb 4.

引用本文的文献

Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.

J Clin Lab Anal. 2024 Sep;38(17-18):e25072. doi: 10.1002/jcla.25072. Epub 2024 Sep 12.

Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.

J Clin Lab Anal. 2022 Jul;36(7):e24375. doi: 10.1002/jcla.24375. Epub 2022 Mar 30.

Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma.

Cancers (Basel). 2021 Jan 12;13(2):256. doi: 10.3390/cancers13020256.

Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.

Indian J Med Res. 2016 Oct;144(4):536-543. doi: 10.4103/0971-5916.200890.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.

作者信息

出版信息

相似文献

引用本文的文献